HLB PEP Registers Vasopressin API for Antidiuretic Hormone with US FDA
HLB Peptide has completed the registration of its Active Pharmaceutical Ingredient (API) for the antidiuretic hormone therapy drug vasopressin in the Drug Master File (DMF) of the U.S. Food and Drug Administration (FDA).
According to HLB Peptide on July 27, the FDA DMF registration has enabled the company to establish a foundation for supplying vasopressin API to pharmaceutical companies in the United States and globally. The DMF system is used to register and manage data on the manufacturing process, quality control, and stability of APIs with the FDA. This data serves as core documentation to prove the quality and manufacturing reliability of the API when a finished pharmaceutical drug manufacturer applies for approval.
This FDA DMF registration is significant as it reflects that HLB Peptide’s peptide synthesis technology and GMP-based quality control capabilities have been recognized by global regulatory agencies. With this, the company has expanded its major peptide API portfolio from existing leuprolide and ganirelix to include vasopressin, further strengthening its competitiveness in the global CDMO (Contract Development and Manufacturing Organization) business. In addition, HLB Peptide plans to accelerate the development of new peptide APIs such as those in the GLP-1 class, and to further expand its portfolio of high value-added peptide APIs.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Shim Kyungjae, CEO of HLB Peptide, stated, "Following our status as the first in Korea to register vasopressin in the MFDS DMF, we have now also completed FDA DMF registration in the United States, laying an important foundation for entering the global market. Going forward, we plan to expand collaboration opportunities with global pharmaceutical companies and continuously strengthen our peptide API portfolio to enhance our competitiveness in the global CDMO business."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.